{"title":"在印度三级保健中心的医学肿瘤诊所的晚期血管内皮瘤的管理和结果。","authors":"Ghazal Tansir, Sameer Rastogi, Adarsh Barwad, Rajni Yadav, Shamim Ahmed Shamim, Ekta Dhamija, Rambha Pandey, Rakesh Garg, Shakti Shrivastava","doi":"10.2144/fsoa-2021-0132","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Hemangioendotheliomas (HEs) are malignant vascular tumors with sparse descriptions in literature owing to their rarity.</p><p><strong>Study design: </strong>Ours is a retrospective study among patients of advanced HEs registered between September 2015 and April 2021.</p><p><strong>Results: </strong>There were 13 patients with median age 34.6 (range: 4-69 years), male preponderance (69%) and predominant subtype of epithelioid HE (76.9%). Common primary sites were viscera (46.2%) and bone (30.8%). Tyrosine kinase inhibitors (TKIs) yielded objective responses in 30% patients whereas chemotherapy only produced disease stabilization in 7.7%.</p><p><strong>Conclusion: </strong>We recognize an aggressive subset of HEs with manifestations such as acute liver failure and splenic rupture. Currently no biomarkers predict the efficacy of TKIs over chemotherapy; however, TKIs showed promising outcomes in this series.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"8 10","pages":"FSO827"},"PeriodicalIF":2.4000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979162/pdf/","citationCount":"1","resultStr":"{\"title\":\"Management and outcomes of advanced hemangioendothelioma at a medical oncology clinic in an Indian tertiary care center.\",\"authors\":\"Ghazal Tansir, Sameer Rastogi, Adarsh Barwad, Rajni Yadav, Shamim Ahmed Shamim, Ekta Dhamija, Rambha Pandey, Rakesh Garg, Shakti Shrivastava\",\"doi\":\"10.2144/fsoa-2021-0132\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>Hemangioendotheliomas (HEs) are malignant vascular tumors with sparse descriptions in literature owing to their rarity.</p><p><strong>Study design: </strong>Ours is a retrospective study among patients of advanced HEs registered between September 2015 and April 2021.</p><p><strong>Results: </strong>There were 13 patients with median age 34.6 (range: 4-69 years), male preponderance (69%) and predominant subtype of epithelioid HE (76.9%). Common primary sites were viscera (46.2%) and bone (30.8%). Tyrosine kinase inhibitors (TKIs) yielded objective responses in 30% patients whereas chemotherapy only produced disease stabilization in 7.7%.</p><p><strong>Conclusion: </strong>We recognize an aggressive subset of HEs with manifestations such as acute liver failure and splenic rupture. Currently no biomarkers predict the efficacy of TKIs over chemotherapy; however, TKIs showed promising outcomes in this series.</p>\",\"PeriodicalId\":12568,\"journal\":{\"name\":\"Future Science OA\",\"volume\":\"8 10\",\"pages\":\"FSO827\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979162/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Science OA\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2144/fsoa-2021-0132\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Science OA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2144/fsoa-2021-0132","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Management and outcomes of advanced hemangioendothelioma at a medical oncology clinic in an Indian tertiary care center.
Aim: Hemangioendotheliomas (HEs) are malignant vascular tumors with sparse descriptions in literature owing to their rarity.
Study design: Ours is a retrospective study among patients of advanced HEs registered between September 2015 and April 2021.
Results: There were 13 patients with median age 34.6 (range: 4-69 years), male preponderance (69%) and predominant subtype of epithelioid HE (76.9%). Common primary sites were viscera (46.2%) and bone (30.8%). Tyrosine kinase inhibitors (TKIs) yielded objective responses in 30% patients whereas chemotherapy only produced disease stabilization in 7.7%.
Conclusion: We recognize an aggressive subset of HEs with manifestations such as acute liver failure and splenic rupture. Currently no biomarkers predict the efficacy of TKIs over chemotherapy; however, TKIs showed promising outcomes in this series.
期刊介绍：
Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
